Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Alger Capital Appreciation Fund et al v. Biomarin Pharmaceutical Inc et al
Case Number:
3:23-cv-00826
See also:
Court:
Nature of Suit:
Judge:
Firms
-
July 23, 2024
Chancery Slams 'Squishy' Deal In 'Tagalong' BioMarin Suit
A visibly irritated Delaware Chancery Court judge on Tuesday rejected a settlement with BioMarin Pharmaceuticals Inc. that would have given shareholder attorneys $1.25 million in exchange for broad releases and "squishy" governance reforms, saying he didn't want to encourage "tagalong litigation" that yielded only "ephemeral" benefits.
-
February 24, 2023
BioMarin Hid 'Revolutionary' Drug's Troubles, Investor Says
California-based BioMarin Pharmaceutical Inc. and two of its executives face an investor suit accusing them of failing to disclose troubles facing its "revolutionary" Hemophilia A gene therapy Valrox during its testing and approval process, while at the same time selling off "uncharacteristically" large amounts of BioMarin stock at artificially inflated prices.